ATE279212T1 - 2-methoxyestradiol-induzierte apoptosis in krebszellen - Google Patents

2-methoxyestradiol-induzierte apoptosis in krebszellen

Info

Publication number
ATE279212T1
ATE279212T1 AT97934286T AT97934286T ATE279212T1 AT E279212 T1 ATE279212 T1 AT E279212T1 AT 97934286 T AT97934286 T AT 97934286T AT 97934286 T AT97934286 T AT 97934286T AT E279212 T1 ATE279212 T1 AT E279212T1
Authority
AT
Austria
Prior art keywords
methoxyestradiol
cancer cells
treatment
meoe2
induced apoptosis
Prior art date
Application number
AT97934286T
Other languages
German (de)
English (en)
Inventor
Tapas Mukhopadhyay
Jack A Roth
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE279212T1 publication Critical patent/ATE279212T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97934286T 1996-07-30 1997-07-24 2-methoxyestradiol-induzierte apoptosis in krebszellen ATE279212T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/688,613 US5958892A (en) 1996-07-30 1996-07-30 2-methoxyestradiol-induced apoptosis in cancer cells
PCT/US1997/012998 WO1998004291A1 (en) 1996-07-30 1997-07-24 2-methoxyestradiol-induced apoptosis in cancer cells

Publications (1)

Publication Number Publication Date
ATE279212T1 true ATE279212T1 (de) 2004-10-15

Family

ID=24765087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934286T ATE279212T1 (de) 1996-07-30 1997-07-24 2-methoxyestradiol-induzierte apoptosis in krebszellen

Country Status (8)

Country Link
US (3) US5958892A (enExample)
EP (1) EP0921821B1 (enExample)
JP (1) JP2000517299A (enExample)
AT (1) ATE279212T1 (enExample)
AU (1) AU723401B2 (enExample)
CA (1) CA2262533A1 (enExample)
DE (1) DE69731213T2 (enExample)
WO (1) WO1998004291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
BR9915940A (pt) * 1998-12-02 2001-09-11 Pfizer Prod Inc Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
US6548541B1 (en) * 1999-04-21 2003-04-15 Unitech Pharmaceuticals, Inc. Carboplatin analogs for cancer treatment
EP1175219A1 (en) * 1999-05-12 2002-01-30 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US6730665B1 (en) 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US7691567B2 (en) 2000-10-30 2010-04-06 Board Of Regents, The University Of Texas System Methods and compositions relating to fortilin, an anti-apoptotic molecule, and modulators of fortilin
WO2002062348A1 (en) * 2001-02-05 2002-08-15 Oncology Sciences Corporation Eugenol, optionally in combination with 2-methoxyestradiol, as a cancer chemopreventative agent
MXPA03007856A (es) * 2001-03-30 2003-12-04 Us Health Derivado de geldanamicina y metodo de usarlo para tratar cancer.
AU2003208913A1 (en) * 2002-01-30 2003-09-02 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) * 2002-03-01 2003-09-12 Entremed, Inc. New methods of using antiangiogenic agents
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
DK1530482T3 (da) 2002-07-18 2014-01-20 Helix Biopharma Corp Brug af urease til at hæmme vækst af cancerceller
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
KR20050098244A (ko) * 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
US7160908B2 (en) * 2003-03-04 2007-01-09 Unitech Pharmaceuticals, Inc. Dynamic anticancer platinum compounds
AU2004275693A1 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
JP2007529426A (ja) * 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
WO2006032026A2 (en) * 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
WO2006058298A2 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
WO2007109312A2 (en) * 2006-03-20 2007-09-27 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20080234243A1 (en) * 2007-01-31 2008-09-25 Lavallee Theresa M Method of treating amyloidosis mediated diseases
US9029322B2 (en) 2007-06-05 2015-05-12 Cornell University Compounds for enhancing p21 expression and methods of use thereof
KR20090009637A (ko) * 2007-07-20 2009-01-23 삼성전자주식회사 엠비-오에프디엠 시스템 및 프레임 바운더리 검출 방법
SG11201803768WA (en) 2015-10-08 2018-06-28 Univ Utah Res Found Methods and compositions for preventing or treating cancer
KR101837735B1 (ko) * 2016-08-08 2018-04-19 성균관대학교산학협력단 TCTP (Translationally controlled tumour protein) 단백질을 포함하는 난모세포(oocytes) 노화 방지 또는 수정능력 개선용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
ATE161039T1 (de) 1988-10-31 1997-12-15 Univ California Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
EP0390323B2 (en) 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
IE911115A1 (en) 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0931830B1 (en) 1993-02-16 2001-03-07 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and phophylaxis of neoplasia
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
US5643900A (en) 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
NZ269156A (en) 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.

Also Published As

Publication number Publication date
CA2262533A1 (en) 1998-02-05
DE69731213T2 (de) 2006-02-23
EP0921821A1 (en) 1999-06-16
WO1998004291A1 (en) 1998-02-05
US20030099614A1 (en) 2003-05-29
AU3738397A (en) 1998-02-20
JP2000517299A (ja) 2000-12-26
AU723401B2 (en) 2000-08-24
US5958892A (en) 1999-09-28
US6410029B1 (en) 2002-06-25
DE69731213D1 (de) 2004-11-18
EP0921821B1 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
ATE279212T1 (de) 2-methoxyestradiol-induzierte apoptosis in krebszellen
Nogueira et al. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
NO885769D0 (no) Fremgangsmaate for lagring, utdeling og applisering av kirurgiske heftstifter.
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
ATE273386T1 (de) Menschliches cyclin e
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
AU6998791A (en) Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation
EP1322307A4 (en) METHOD FOR THE TREATMENT OF CELL PROLIFERATION TROUBLES AND VIRUS INFECTIONS
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
AU2002246668A1 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
ES2161655A1 (es) Procedimiento para determinar la capacidad invasiva y metastasica de un tumor epitelial mediante el uso de snail.
EE9900450A (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
NZ524936A (en) Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
WO2000013015A8 (en) Modulating multiple lineage kinase proteins
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
DE60036105D1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
NO884770D0 (no) Fremgangsmaate for fremstilling av di-t-butylfenoler, og mellomprodukt for anvendelse ved denne.
PT782630E (pt) Gene da doenca poliquistica do rim
NO990450L (no) Behandling av sinnslidelser
EP0876507A4 (en) CONTROL AND CONTROL OF THE EXPRESSION OF THE PROTEIN PHOSPHATASE 2C-PP2C-ALPHA IN TUMOR CELLS IN TUMOR THERAPY, PREVENTION AND DETERMINATION
NO20005548L (no) Mykobakterieinhibitorer
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties